January 22nd 2025
President Donald Trump is looking to cut federal spending, but given his focus on national security, hospitals and health systems could get some sorely needed help.
December 24th 2024
2025 GI Satellite Symposia in San Francisco
January 23-24, 2025
Register Now!
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Medical Crossfire®: Real World Strategies to Improve Therapeutic Durability and Outcomes in CLL
February 20, 2025
Register Now!
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Exploring the Benefits and Risks of AI in Oncology
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care
View More
Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma
View More
Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes
View More
Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval
View More
Cybersecurity: How the World Measures Up, Country by Country
July 6th 2017The UN has released its annual report on global cybersecurity. The report aims to measure which countries are most committed to making the web more secure, scoring countries according to five pillars: technical, organizational, legal, cooperation and growth potential.
Should Healthcare Systems Be Concerned About Hidden Cobra?
June 21st 2017Another week, another IT security threat with a conveniently catchy name: the U.S. Department of Health and Human Services late last week released a warning about a new threat, or series of threats, that could impact healthcare systems.
ReadyDock's David Engelhardt on Technology to Kill MRSA, C. Diff
March 1st 2017In Part 2 of his interview with HCA News, David Engelhardt, the founder of ReadyDock Inc., discussed the company's chemical-free mobile and tablet disinfection device designed to mitigate the burden of hospital-acquired infections. Here, Engelhardt details how ReadyDock’s technology works and infection-causing bacteria it can kill.
ReadyDock's David Engelhardt Talks Hospital-Acquired Infections
March 1st 2017David Engelhardt, the founder of ReadyDock Inc., met up with HCA News for an interview at the HIMSS17 conference in Orlando, Florida. ReadyDock is chemical-free mobile and tablet disinfection device designed to mitigate the burden of hospital-acquired infections. In this section, Engelhardt speaks of the severity and complexity of the infection issue.